Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Shares Outstanding: 2019-2024

Historic Shares Outstanding for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $70.6 million.

  • C4 Therapeutics' Shares Outstanding rose 5.12% to $74.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year increase of 5.12%. This contributed to the annual value of $70.6 million for FY2024, which is 16.80% up from last year.
  • C4 Therapeutics' Shares Outstanding amounted to $70.6 million in FY2024, which was up 16.80% from $60.5 million recorded in FY2023.
  • C4 Therapeutics' Shares Outstanding's 5-year high stood at $70.6 million during FY2024, with a 5-year trough of $43.1 million in FY2020.
  • Moreover, its 3-year median value for Shares Outstanding was $60.5 million (2023), whereas its average is $60.0 million.
  • Data for C4 Therapeutics' Shares Outstanding shows a peak YoY skyrocketed of 2,918.25% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows C4 Therapeutics' Shares Outstanding stood at $43.1 million in 2020, then grew by 13.07% to $48.7 million in 2021, then rose by 0.57% to $49.0 million in 2022, then climbed by 23.49% to $60.5 million in 2023, then climbed by 16.80% to $70.6 million in 2024.